- SEK40.57bn
- SEK36.61bn
- SEK2.27bn
Brief: Camurus Gets EMA Acceptance Of MAA Filing For Octreotide SC Depot
Brief: Camurus Board Proposed No Dividend Should Be Paid
Brief: Camurus Q1 Net Income SEK 78 Million
Brief: Camurus Sees FY Total Rev Of SEK 1,740-1,860 Mln
Brief: Camurus Q4 EBIT SEK -29 Million
Brief: Camurus Intends To Carry Out A Directed Share Issue Of About 2 Mln Shares
Brief: Camurus Submits New Drug Application To FDA
Brief: Camurus To Enter Large Cap Segment On Nasdaq Stockholm
Europe Research Roundup: Entain, Fresenius Medical Care, Indivior
Brief: Camurus Q3 Net Income SEK 86 Million
Europe Research Roundup: Duerr, Sika AG, Tomra Systems ASA
Brief: Camurus Says Fy Guidance For Total Revenues Is Increased To SEK 1,640-1,720 Million From SEK 1,530-1,650 Million
Brief: Camurus Reiterates 2023 Financial Outlook
Brief: Camurus Q2 Net Income SEK 301 Million
Brief: Camurus Announces New Phase 3 Data
Brief: Camurus' CAM2029 Achieves Superior Treatment Response Compared To Placebo In Phase 3 Acromegaly Trial
Brief: Camurus Announces FDA Approval Of Brixadi For Treatment Of Moderate To Severe Opioid Use Disorder
Brief: Camurus Announces FDA Approval Of Brixadi For The Treatment Of Moderate To Severe Opioid Use Disorder
Brief: Camurus Keeps Financial Outlook For 2023